Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: g.w. barnard who wrote (9245)	6/5/1998 5:44:00 PM
From: blankmind	Read Replies (1) \| Respond to of 23519

- I think VLAD is right on one point: - Leland has to keep repeating the fact that VVUS is working on an arsenal of drugs. MUSE was only the tip of the iceberg. - And then if Leland says he's considering alternative ways of producing these drugs, such as allowing his VIvus to be bought out, then holy cow - this will be the mother of all short squeezes & we could see $100+.

To: g.w. barnard who wrote (9245)	6/5/1998 7:21:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

[ Business \| US Market \| Industry \| IPO \| S&P \| International \| PRNews \| BizWire \| Finance Home ] -------------------------------------------------------------------------------- Friday June 5, 1:58 pm Eastern Time Company Press Release Harvard Scientific Achieves Another Milestone as Management Predicts Product Success LAKE MARY, Fla.--(BUSINESS WIRE)--June 5, 1998--Harvard Scientific Corp., (OTC Bul Bd: HVSF) a Nevada corporation, announced today that results from an ongoing stability study for its patented lyophilized liposomal Prostaglandin E-1 (''LLPGE1'') has proven that it remains stable at room temperature for at least 12-months without any degradation of the active drug agent. The Company cites this ongoing study as further proof that its product will become the treatment of choice by physicians and their sexual dysfunction patients. The convenience of not having to refrigerate also provides the Company a very competitive advantage over other intrameatal delivery treatment products due to cost savings in its manufacturing and distribution practices. This significant advantage will become more valuable as the product begins shipping on a global basis. Thomas E. Waite, the Company's President and CEO stated, ''over the last couple of months we have experienced an extreme shake-out in the sexual dysfunction product market due to Pfizer's introduction of Viagra. Vivus's and Pharmacia's sales have plummeted and their market presence is almost non-existent. This could obviously be catastrophic to a corporation, especially to Vivus which currently relies on only one product (MUSE(R)) for its sales. Even though the media is reporting potential life threatening systemic adverse effects for users of Pfizer's oral medication treatment, it has created euphoria within the marketplace and Wall Street. Apparently at this time, the patient is willing to assume the risk of these systemic effects because no currently available alternative therapy provides satisfactory results. The Company is confident that it will be successful in its ongoing clinical trials and when its product is approved for marketing, patients will readily accept it as their treatment of choice.'' ''The Company is firm in its belief that Prostaglandin E-1 (a very powerful vasodilator), is the most effective treatment agent available for both male and female sexual dysfunction patients and it will become the accepted medical standard as a locally delivered therapeutic aid for this malady,'' stated Darryl M. See, the Company's Medical Director of Clinical Affairs. ''The Company's patented ability to stabilize this agent in lyophilized liposomes, reconstitute the agent into an aqueous (liquid) solution and painlessly deliver the active agent via a tiny applicator tip (approximately one-half inch in length) intrameatally at the local area of the problem will become the most requested method of treatment by patients that do not wish to experience the potential, life threatening adverse systemic effects of current oral delivery treatments.'' Prostaglandin E-1 is a naturally occurring vasodilator originally approved by the U.S. Food and Drug Administration for intravenous infusion in neonates. In 1995, PGE-1 was approved by the FDA for use in Pharmacia & Upjohn Inc.'s (NYSE: PNU - news) Caverject(R), which is administered by needle injection as a treatment for male erectile dysfunction. In November 1996, Vivus, Inc.'s (NASDAQ: VVUS - news) MUSE(R) delivery system was approved by the FDA. Recently, the FDA approved PGE-1 again by needle administration via Edex(R), (Schwartz-Pharma). Viagra(R), Pfizer, Inc.'s (NYSE: PFE - news) oral medication treatment was approved by the FDA in March, 1998. Zonagen Inc. (NASDAQ: ZONA - news) has in development an oral treatment product as well. The Company believes that its product represents a substantial treatment advantage over other delivery systems currently being utilized in the industry. From time to time the Company may issue forward looking statements which involve risks and uncertainties. This statement may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results could differ and any forward looking statements should be considered accordingly. -------------------------------------------------------------------------------- More Quotes and News: Harvard Scientific Corp (OTC BB:HVSF - news) Pfizer Inc (NYSE:PFE - news) Pharmacia & Upjohn Inc (NYSE:PNU - news) Vivus Inc (Nasdaq:VVUS - news) Zonagen Inc (Nasdaq:ZONA - news) Related News Categories: biotech, medical/pharmaceutical -------------------------------------------------------------------------------- Help -------------------------------------------------------------------------------- Copyright c 1998 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form. See our Important Disclaimers and Legal Information. Questions or Comments? gw, HVSF is a two man scam that thinks they can infringe on Vivus's patented delivery system. They may have learned how to freeze dry the drug but its too bad that they won't be able to deliver it transurethrally for another seven years. By then there will be MUSE10 and HVSF will be another one of those wanna be BB stocks. One thing I must say though--Vivus needs to hire the guy who constantly posts the HVSF bs all over the internet. At least he is a great spin doctor. I guess that means they will have to hire 1/2 of the company. Maybe Vivus can also freeze dry prostaglandins if it really works and does not require refridgeration. There is no patent for freeze drying a drug--if can be done in liposomes then it probably be done in another substance.